MS30.05 Nutritional Management During Radical Radiotherapy

Abstract

therefore lowering toxicity and potentially opening the door to reassessment of RT dose intensification. Finally, with the explosion of evidence-based applications of immunotherapy in metastatic lung cancer and the demonstration of an impressive survival prolongation in the Phase III randomized PACIFIC trial with the addition of maintenance durvalumab following chemo-RT, the role of chemotherapy may be eventually challenged and reevaluated in Stage III NSCLC, to be possibly replaced by concurrent immunotherapy or a chemo-immunotherapy combination.